Beijing Chenguang Pharmaceutical Technology Co., Ltd.

Primary objective To evaluate the efficacy of CG2001 in treating Chinese adult male subjects with androgenetic alopecia (AGA) and determine the recommended dose for Phase III clinical trials. Secondary objective To evaluate the safety of CG2201 in treating Chinese adult male subjects with AGA at the target dose.

Main purpose: A single-center, randomized, open, two-period crossover, single-dose, fasting and postprandial administration design was used to compare the differences in the degree and rate of absorption of fexofenadine hydrochloride dry suspension (30 mg) provided by Chenguang (Tianjin) Pharmaceutical Co., Ltd. and fexofenadine hydrochloride dry syrup (trade name: Allegra®, specification: 30 mg) produced by Sanofi Co., Ltd. in healthy Chinese people. Secondary purpose: Evaluate the safety of fexofenadine hydrochloride dry suspension (specification: 30 mg) provided by Chenguang (Tianjin) Pharmaceutical Co., Ltd. and fexofenadine hydrochloride dry syrup (trade name: Allegra®, specification: 30 mg) produced by Sanofi Co., Ltd. under fasting and postprandial conditions.

Primary objective: This study used finasteride tablets (5 mg) from Chenguang (Tianjin) Pharmaceutical Co., Ltd. as the test preparation and finasteride tablets (trade name: Proscar®, specification: 5 mg) from Merck Sharp & Dohme Limited as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation when administered under fasting and postprandial conditions. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.